PRME Q3 2024 Earnings — Prime Medicine, Inc. Revenue & Financial Results | Market Cap Arena

PRMEPrime Medicine, Inc.

$771M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$209,000

Gross Profit

$209,000100.0% margin

Operating Income

-$54M-25948.3% margin

Net Income

-$53M-25128.2% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$27M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$333M

Total Liabilities

$143M

Stockholders' Equity

$190M

Cash & Equivalents

$118M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$209,000	$0	—
Gross Profit	$209,000	$0	—
Operating Income	-$54M	-$51M	-5.4%
Net Income	-$53M	-$51M	-3.6%